Enliven Therapeutics, Inc. (ELVN) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 6 Buy.
The consensus price target is $43.33 (low: $39.00, high: $52.00), representing a downside of 3.4% from the current price $44.85.
Analysts estimate Earnings Per Share (EPS) of $-1.95 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.89 vs est $-1.95 (beat +2.9%). 2025: actual $-1.83 vs est $-1.74 (missed -5.5%). Analyst accuracy: 96%.
ELVN Stock — 12-Month Price Forecast
$43.33
▼ -3.39% Downside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Enliven Therapeutics, Inc., the average price target is $43.33, with a high forecast of $52.00, and a low forecast of $39.00.
The average price target represents a -3.39% change from the last price of $44.85.
Highest Price Target
$52.00
Average Price Target
$43.33
Lowest Price Target
$39.00
ELVN Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to Enliven Therapeutics, Inc. in the past 3 months
EPS Estimates — ELVN
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.89
vs Est –$1.95
▲ 3.0% off
2025
Actual –$1.83
vs Est –$1.74
▼ 5.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ELVN
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
